Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking-Reference-Cited by-同舟云学术

Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking

Published:2020-06-08 Issue:7 Volume:111 Page:2508-2525
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Lanotte Romain¹,Garambois Véronique¹,Gaborit Nadège¹,Larbouret Christel¹,Musnier Astrid²,Martineau Pierre¹,Pèlegrin André¹,Chardès Thierry¹³^ORCID

Affiliation:

1. Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194 Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) Montpellier France

2. MAbSilico SAS Centre de Recherche INRA Val de Loire Nouzilly France

3. Centre National de la Recherche Scientifique (CNRS) Paris France

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14458

Reference52 articles.

1. The ErbB/HER family of protein-tyrosine kinases and cancer

2. Potential of ErbB4 antibodies for cancer therapy

3. Prognostic value of ERBB4 expression in patients with triple negative breast cancer

4. Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HER4 Affects Sensitivity to Tamoxifen and Abemaciclib in Luminal Breast Cancer Cells and Restricts Tumor Growth in MCF-7-Based Humanized Tumor Mice;International Journal of Molecular Sciences;2024-07-08

2. “Shedding” light on HER4 signaling in normal and malignant breast tissues;Cellular Signalling;2022-09